Reach Us +44-1647-403003
Neoadjuvant Chemotherapy with S-1 for Patients with Oral Squamous Cell Carcinoma | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Neoadjuvant Chemotherapy with S-1 for Patients with Oral Squamous Cell Carcinoma

Hidetaka Yokoe1, Atsushi Kasamatsu2,3*, Katsunori Ogawara2, Takashi Ishigami2, Yasunori Sato1, Masashi Shiiba2, Hideki Tanzawa2,3 and Katsuhiro Uzawa2,3*

1Department of Oral and Maxillofacial Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

2Division of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

3Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

*Corresponding Author:
Dr. Atsushi Kasamatsu
Department of Clinical Molecular Biology
Graduate School of Medicine, Chiba University
1-8-1 Inohana, Chuo-ku
Chiba 260-8670, Japan
Tel: +81-43-226-2300
Fax: +81-43-226-2151
E-mail: [email protected]
Dr. Katsuhiro Uzawa
Department of Clinical Molecular Biology
Graduate School of Medicine
Chiba University, 1-8-1 Inohana
Chuo-ku, Chiba 260-8670, Japan
E-mail: [email protected]

Received Date: July 06, 2010; Accepted Date: August 24, 2010; Published Date: August 24, 2010

Citation: Yokoe H, Kasamatsu A, Ogawara K, Ishigami T, Sato Y, et al. (2010) Neoadjuvant Chemotherapy with S-1 for Patients with Oral Squamous Cell Carcinoma. J Cancer Sci Ther 2: 132-135. doi:10.4172/1948-5956.1000038

Copyright: © 2010 Yokoe H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


S-1, an oral anticancer drug, is comprised of tegafur (a prodrug of 5-fluorouracil) and two biochemical modulators that have effect-enhancing and adverse reaction-reducing activities. Neoadjuvant chemotherapy (NAC) using S-1 has not been reported. Between April 2003 and March 2008, 103 patients with previously untreated oral squamous cell carcinoma (OSCC) received some courses of S-1 NAC (S-1 80 mg/m2/day as the NAC until 1 week preoperatively). Tumor size and histopathologic effect were evaluated before and after treatment. Among 103 cases, 10 cases had complete responses and 53 cases had partial responses (overall response rate [RR], 61.2%). Twenty-two (21.4%) patients had adverse events. Most patients had mild toxicities in the bone marrow and digestive tract (grade 1, 19 cases). Only three patients (2.9%) had grade 2 neutropenia or grade 4 thrombocytopenia. We examined the relationship between the RR and the clinicopathologic behaviors. The RR of the pN2 cases (33.3%) was significantly lower than that of the pN0 cases (69.4%). The RR was not correlated with tumor size, differentiation type, distant metastasis, and the period of administration. The data indicates that S-1 caused only mild toxicity and had highly effective antitumor activity. Furthermore, the RR of S-1 NAC might predict regional lymph node metastasis.


Share This Page